Rohto Pharmaceutical Co ( (JP:4527) ) has provided an announcement.
Rohto Pharmaceutical Co., Ltd. announced a decision by its Board of Directors to repurchase up to 2,430,000 of its own shares, representing approximately 1.07% of the total issued shares, with a total repurchase price of up to ¥5 billion. This strategic move aims to enhance return on equity and earnings per share, while also facilitating fundraising efforts by mitigating short-term demand and supply impacts associated with the issuance of Zero Coupon Convertible Bonds due in 2032.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of healthcare products, including over-the-counter medicines, skincare products, and other health-related goods. The company is known for its innovative solutions and has a significant presence in the Asian market.
YTD Price Performance: -14.49%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.54B
See more data about 4527 stock on TipRanks’ Stock Analysis page.